Venture capital at Bayer Crop Science, which has until now focused mainly on investing in external funds, is just beginning to firm up with the creation of Bayer Growth Ventures (BGV). But there are still a lot of unknowns.
Estes is a prominent figure in the agriculture biotech scene, having held technology leadership roles at prominent companies including DuPont, Monsanto and Syngenta, as well as for small startups and venture funds.
While it was a positive first step that the FDA addressing the space, how it will play out is still uncertain as participants debated who should regulate the products, what it should be called, and how its safety will be determined.
Bayer, through Condon, has indicated that it is aware the merger presents an opportunity to reset public opinion about controversial technologies like GMOs and Dicamba, but the executive announcement last week suggests a complete overhaul is not in the cards.
As the eventual conclusion of Bayer’s acquisition of Monsanto draws closer, all eyes are on the German healthcare and agriculture giant to find out what the new normal will look like. In agriculture, Liam Condon, CEO of Bayer CropScience, will have the primary role in shaping that new reality.
Monsanto Growth Ventures, the venture arm of Monsanto, has lost all of its dedicated staff after former managing director John Hamer, former investment director Kiersten Stead and former principal Ryan Rakestraw all left within a month of each other.
A publicly available and editable list of women leaders in agriculture, started by Agrilyst CEO Allison Kopf, challenges event and conference organizers to increase gender representation in public discussions of the industry.
Tyson Ventures has been tight-lipped on what might come next for the corporate VC, but at the Future Food Tech Conference, managing director Reese Schroeder offered some insight into what might be ahead for the protein giant.